Compugen Ltd. (CGEN)
NASDAQ: CGEN · Real-Time Price · USD
2.350
+0.015 (0.64%)
At close: Jul 31, 2026, 4:00 PM EDT
2.380
+0.030 (1.28%)
After-hours: Jul 31, 2026, 7:49 PM EDT
[Name] Revenue
Compugen had revenue of $2.18M in the quarter ending March 31, 2026, a decrease of -4.73%. This brings the company's revenue in the last twelve months to $72.66M, up 163.35% year-over-year. In the year 2025, Compugen had annual revenue of $72.76M with 161.14% growth.
Revenue (ttm)
$72.66M
Revenue Growth
+163.35%
P/S Ratio
3.06
Revenue / Employee
$968,747
Employees
75
Market Cap
222.27M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 72.76M | 44.90M | 161.14% |
| Dec 31, 2024 | 27.86M | -5.60M | -16.72% |
| Dec 31, 2023 | 33.46M | 25.96M | 346.12% |
| Dec 31, 2022 | 7.50M | 1.50M | 25.00% |
| Dec 31, 2021 | 6.00M | 4.00M | 200.00% |
| Dec 31, 2020 | 2.00M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 17.80M | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | 712.00K | -8.57M | -92.33% |
| Dec 31, 2015 | 9.28M | -3.09M | -24.99% |
| Dec 31, 2014 | 12.37M | 8.82M | 248.46% |
| Dec 31, 2013 | 3.55M | 3.31M | 1,366.53% |
| Dec 31, 2012 | 242.00K | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | 1.12M | 865.00K | 346.00% |
| Dec 31, 2009 | 250.00K | -88.00K | -26.04% |
| Dec 31, 2008 | 338.00K | 158.00K | 87.78% |
| Dec 31, 2007 | 180.00K | -35.00K | -16.28% |
| Dec 31, 2006 | 215.00K | -431.00K | -66.72% |
| Dec 31, 2005 | 646.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MacroGenics | 157.08M |
| Cellectis | 75.11M |
| Coherus Oncology | 46.88M |
| Orchestra BioMed Holdings | 32.72M |
| ProQR Therapeutics | 15.73M |
| Capricor Therapeutics | 11.13M |
| Whitehawk Therapeutics | 7.15M |
| AC Immune | 4.62M |
CGEN News
- 11 days ago - Compugen to Participate in BTIG Biotechnology Conference 2026 - PRNewsWire
- 12 days ago - Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026 - PRNewsWire
- 22 days ago - Compugen management to meet virtually with Lake Street - TheFly
- 6 weeks ago - Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress - PRNewsWire
- 6 weeks ago - Compugen Transcript: Fireside chat - Transcripts
- 7 weeks ago - Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026 - PRNewsWire
- 7 weeks ago - Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development - PRNewsWire
- 2 months ago - Compugen price target lowered to $5 from $13 at Leerink - TheFly